Director of Foundation Board

Andreas Bergmann has worked in the diagnostic industry as researcher and entrepreneur for over 25 years. He founded the Waltraut Bergmann Stiftung, named after his mother, for supporting research in fields of unmet medical needs. His philosophy is that diagnosis and methods of treatments are to aid in the prevention of diseases rather than having to cure them. Bergmann is highly passionate about research in the fields of cancer and sepsis.

With an outstanding track record, he has spearheaded the discovery, validation and the development of blood biomarkers. Bergmann was one of the founders and managers of B.R.A.H.M.S. AG where the sepsis marker Procalcitonin (PCT®) was developed under his responsibility as Chief Research Officer. B.R.A.H.M.S. AG started as a management buy-out with 180 employees 1994 and grew to approx. 400 employees by 2009. The biomarker Procalcitonin created a new diagnostic standard of care supporting patient management in sepsis. Andreas Bergmann is inventor holding 121 patent rights and also co-author of over 150 peer-reviewed scientific publications.

Bergmann went on to establish sphingotec which is located in Hennigsdorf. He leads the development of diagnostic methods for the prediction, prevention, intervention strategies and early treatment of diseases in the fields of cancer, cardiovascular diseases and acute care. Focusing on plasma biomarkers to indicate the susceptibility of a specific disease, the resulting information can enable monitoring, prevention and intervention strategies

Bergmann is also member of the Executive Board the Adrenomed AG. The Adrenomed AG develops a medicament for preventing and treatment of spetic shock.

Andreas Bergmann studied biochemistry at the Freie Universität Berlin (free university Berlin) and later obtained a PhD in biochemistry at the Technische Universität Berlin (technical university Berlin) in 1987.